Enzovexa

Enzovexa contains tofacitinib, an oral targeted synthetic disease-modifying antirheumatic drug that inhibits Janus kinase signalling involved in immune-mediated inflammation. Under specialist supervision, it may be used in approved immune-mediated inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.